Merck sign $303 million biotherapeutics deal

PharmaTimes has reported that Merck & Co has entered into a possible $303 million USD collaboration with Ambrx to develop ‘smart bomb’ antibodies.

Merck hope to develop biologic drug conjugates using Ambrx’s “site-specific protein medicinal chemistry technology”

Merck is paying an upfront fee of $15 million and is eligible to receive milestones totalling up to $288 million. Ambrx will also receive royalties.

Richard Murray, head of biologics and vaccines research at Merck said that this collaboration will allow us to combine Ambrx’s expertise in site-specific protein conjugation chemistry with Merck’s expanding antibody capabilities and extensive small molecule resources.

Click here to see our latest scientifc jobs

Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates

Posted in: Industry News, News
CK Logo in place of featured image